Translational Prospects and Challenges in Human Induced Pluripotent Stem Cell Research in Drug Discovery

Abstract

Despite continuous efforts to improve the process of drug discovery and development, achieving success at the clinical stage remains challenging because of a persistent translational gap between the preclinical and clinical settings. Under these circumstances, the discovery of human induced pluripotent stem (iPS) cells has brought new hope to the drug discovery field because they enable scientists to humanize a variety of pharmacological and toxicological models in vitro. The availability of human iPS cell-derived cells, particularly as an alternative for difficult-to-access tissues and organs, is increasing steadily; however, their use in the field of translational medicine remains challenging. Biomarkers are an essential part of the translational effort to shift new discoveries from bench to bedside as they provide a measurable indicator with which to evaluate pharmacological and toxicological effects in both the preclinical and clinical settings. In general, during the preclinical stage of the drug development process, in vitro models that are established to recapitulate human diseases are validated by using a set of biomarkers; however, their translatability to a clinical setting remains problematic. This review provides an overview of current strategies for human iPS cell-based drug discovery from the perspective of translational research, and discusses the importance of early consideration of clinically relevant biomarkers.

Hit Generation in TB Drug Discovery: From Genome to Granuloma

“…Tissue engineering methods may yield more heterogeneous, yet still organized, multicellular structures that better recapitulate the structure of human granulomas. 256 These types of models will provide physiological relevance, unbiased selection of essential and vulnerable targets at a near organismal level, and simultaneously avoid compounds with unfavorable biophysical properties. Many of the simpler screens established and described above will still be essential for identifying targets and mechanism of action once hits have been identified.…”

The Potential of Induced Pluripotent Stem Cells to Test Gene Therapy Approaches for Neuromuscular and Motor Neuron Disorders

“…Thus far, the introduction of iPSCs into the drug development pipeline has allowed (i) physiologically improved modeling of disease-relevant phenotypes, (ii) a greater patient stratification, and (iii) discrimination between drug responders and non-responders (Pasteuning-Vuhman et al, 2020). In perspective, this will have an impact on the current limitations of the conventional drug discovery process and consequently improve the success of therapeutic target identification and clinical trial outcomes (Hosoya and Czysz, 2016).…”

Stem cell imaging through convolutional neural networks: current issues and future directions in artificial intelligence technology

“…Some examples of ASCs include MSCs, which are responsible for generating bone, cartilage, and fat cells; neural cells, which differentiate into nerve cells, oligodendrocytes, and astrocytes; HSCs, which form progenitor and mature blood cells; and skin stem cells, which produce layers of protective skin (Zakrzewski et al, 2019). In addition, iPSCs are cells generated from adult somatic stem cells through genetic reprogramming (Wasik et al, 2014;Hirschi, Li & Roy, 2014;Hosoya & Czysz, 2016;Cieślar-Pobuda et al, 2017). In 2006, Yamanaka and Takahashi overexpressed four transcription factor genes, encoding Oct4, Sox2, Klf4, and c-Myc into somatic cells, which induced the cells to revert to the pluripotent state (Takahashi & Yamanaka, 2006).…”